BUZZ-Axsome Therapeutics rises on migraine drug trial data

Reuters

Feb 24, 2025

BUZZ-Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on migraine drug trial data

** Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket

** AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments

** Symbravo is a combination of two medicines, meloxicam and rizatriptan

** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says

** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women

** AXSM gained 6.3% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2513721083"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2513721083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2513721083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-24 21:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513721083","market":"us","top_or_hot":-1,"title":"BUZZ-Axsome Therapeutics rises on migraine drug trial data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on migraine drug trial data</title></head><body><p>** Drugmaker Axsome Therapeutics' <span>AXSM.O</span> shares rise 1.6% to $139.98 premarket</p><p>** AXSM <span>says</span> its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments</p><p>** Symbravo is a combination of two medicines, meloxicam and <span>rizatriptan</span></p><p>** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients <span>pain-free </span>within 2 hours, compared <span>with </span>only 1% of patients who took oral CGRP inhibitors<span>, the company says</span></p><p>** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women</p><p>** AXSM gained 6.3% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Axsome Therapeutics rises on migraine drug trial data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Axsome Therapeutics rises on migraine drug trial data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-02-24 21:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on migraine drug trial data</title></head><body><p>** Drugmaker Axsome Therapeutics' <span>AXSM.O</span> shares rise 1.6% to $139.98 premarket</p><p>** AXSM <span>says</span> its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments</p><p>** Symbravo is a combination of two medicines, meloxicam and <span>rizatriptan</span></p><p>** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients <span>pain-free </span>within 2 hours, compared <span>with </span>only 1% of patients who took oral CGRP inhibitors<span>, the company says</span></p><p>** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women</p><p>** AXSM gained 6.3% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3N3PF0VU:1","article_id":"2513721083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513721083","pubTimestamp":1740405590,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Axsome Therapeutics rises on migraine drug trial data** Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket** AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments** Symbravo is a combination of two medicines, meloxicam and rizatriptan** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women** AXSM gained 6.3% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4007":"制药","BK4585":"ETF&股票定投概念","AXSM":"Axsome Therapeutics, Inc."},"translate_title":"BUZZ-Axsome Therapeutics因偏头痛药物试验数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9},"content_text":"BUZZ-Axsome Therapeutics rises on migraine drug trial data** Drugmaker Axsome Therapeutics' AXSM.O shares rise 1.6% to $139.98 premarket** AXSM says its drug, Symbravo, met the main goal in a late-stage trial to treat migraine headaches in patients who didn't respond well to other treatments** Symbravo is a combination of two medicines, meloxicam and rizatriptan** In the trial, Symbravo was found to be more effective than oral CGRP inhibitors in relieving migraine pain, with 47.9% of patients pain-free within 2 hours, compared with only 1% of patients who took oral CGRP inhibitors, the company says** Symbravo is not recommended for people with heart problems, high blood pressure, or kidney disease, or for pregnant or breastfeeding women** AXSM gained 6.3% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}